newsfilter
← Latest News
GlobeNewswire·

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human